Merck & Co. v. Reynolds
The Supreme Court ruled that investors suing Merck over Vioxx had filed their securities fraud lawsuit on time, because the two-year deadline to sue does not start running until investors actually discover, or reasonably should have discovered, facts showing the company acted with intent to deceive — not merely facts suggesting something might be wrong.
The decision clarifies a nationwide standard for when securities fraud lawsuits must be filed, rejecting a company-friendly rule that would have started the clock as soon as investors had any reason to start investigating, even before they could show deliberate deception.
How it got here: A federal trial court dismissed the suit as filed too late; the Third Circuit reversed; Merck asked the Supreme Court to review the timeliness ruling.
The Case in Depth
What happened
A group of investors sued Merck & Co., claiming the company knowingly misrepresented the heart-attack risks of its painkiller Vioxx and that they lost money when the truth came out. Merck had promoted a theory (the "naproxen hypothesis") suggesting a comparison drug, not Vioxx, explained troubling cardiovascular data from a 2000 study, even as regulators and litigants raised concerns about Vioxx's safety in the following year.
The question before the Court
When investors sue a drug company for securities fraud, when does the clock start on the two-year deadline to file — and does it require knowing the company acted with intent to deceive?
The Court's answer
The two-year deadline for filing a private securities fraud suit does not start running until the investor actually discovers, or a reasonably diligent investor would have discovered, the facts that make up the fraud — including facts showing the company acted with intent to deceive, not just carelessness. The Court rejected Merck's argument that the clock should start earlier, once investors had merely enough information to prompt further investigation.
Applying that standard, the Court found that before November 6, 2001 — the cutoff date — neither an FDA warning letter nor product-liability lawsuits against Merck contained enough information about Merck's state of mind to show the company knew its "naproxen hypothesis" was false. Because no such evidence existed before that date, the investors' 2003 complaint was filed in time.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Investors bringing securities fraud claims get more time to build a case, because the clock does not start until they have — or reasonably should have — uncovered evidence of a company's intent to deceive, not just evidence that something seemed off. Companies facing fraud accusations cannot shorten that window merely by pointing to early warning signs or public scrutiny.
What changes now
This is a final merits decision resolving the timeliness question; the case does not return to the trial court on this issue since the Third Circuit's ruling that the suit was timely stands. The underlying securities fraud claims against Merck may now proceed to be litigated on their merits in the lower courts, since the timeliness bar Merck sought has been rejected.
What this does not decide
The Court did not decide whether the plaintiffs' fraud claims are ultimately valid, only that the lawsuit was filed in time. It also expressly declined to say whether a later 2003 study might have triggered the deadline, and did not address what other facts (beyond scienter) must be discovered for a claim to accrue.
Concurrences and dissents
Concurrence — Justice Stevens
Justice Stevens agreed with the Court's bottom line but said most of the Court's lengthy discussion of whether 'discovery' includes constructive discovery (facts a diligent investor should have found) was unnecessary here, since in this case actual and constructive discovery happened at the same time. He would reserve judgment on Justice Scalia's narrower reading of the statute for a case where the distinction actually matters.
Concurrence — Justice Scalia
Justice Scalia, joined by Justice Thomas, agreed the suit was timely but argued the statute requires only actual discovery of fraud, not constructive discovery by a hypothetical diligent investor. He pointed to a related securities statute where Congress explicitly added constructive-discovery language, arguing Congress's choice not to include similar language here means Congress intended only actual discovery to start the clock.
How the Court got there
The legal reasoning, step by step
- The Court first decided that the statutory word 'discovery' in the 2-year filing deadline covers not just facts a plaintiff actually learned, but also facts a reasonably diligent plaintiff would have learned — a standard borrowed from the long-standing 'discovery rule' used in fraud cases generally, and from how every court of appeals had already read a related securities-law deadline before Congress wrote this one.
- The Court then held that among the 'facts constituting the violation' that must be discovered is scienter — the legal term for a company's guilty state of mind, meaning it acted with intent to deceive rather than by mistake or carelessness. Because scienter is a necessary element of this kind of fraud claim and Congress imposed strict pleading rules requiring it to be shown, the discovery clock cannot start until evidence of that intent surfaces.
- The Court rejected Merck's argument that evidence a statement was false is usually enough to also show intent to deceive, reasoning that in securities cases a false or mistaken prediction does not by itself reveal whether the speaker lied on purpose or made an innocent error.
- The Court also rejected Merck's proposed 'inquiry notice' standard, under which the clock would start once investors had enough information to prompt an investigation, even before they found evidence of intentional wrongdoing. The Court found nothing in the statute's text allowing the clock to start before actual or reasonably diligent discovery occurs.
- Applying its standard to the record, the Court found that the FDA's 2001 warning letter and the pending product-liability lawsuits described only general suspicions and inconsistent marketing, without evidence that Merck knew its scientific defense of Vioxx was false, so no reasonably diligent investor could have discovered the necessary facts before the cutoff date.
Doctrinal impact
Cases affected by this decision
Reaffirms Lampf, Pleva, Lipkind, Prupis & Petigrow v. Gilbertson (501 U. S. 350)
The Court relied on Lampf's language adopting a 'discovery of the facts' limitations standard for securities fraud suits.